AR054230A1 - Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante - Google Patents
Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestranteInfo
- Publication number
- AR054230A1 AR054230A1 AR20060100670A ARP060100670A AR054230A1 AR 054230 A1 AR054230 A1 AR 054230A1 AR 20060100670 A AR20060100670 A AR 20060100670A AR P060100670 A ARP060100670 A AR P060100670A AR 054230 A1 AR054230 A1 AR 054230A1
- Authority
- AR
- Argentina
- Prior art keywords
- aerosol
- sequestering agent
- phosphoric acid
- inhaler
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
Formulacion de solucion en aerosol para usar en un inhalador en aerosol que comprende como mínimo un principio activo seleccionado del grupo que consiste en 20-cetoesteroides y derivados de quinolinona, un propelente que contiene un hidrofluoroalcano, y un cosolvente, estabilizada mediante el agregado de una cantidad específica de un agente secuestrante. Reivindicacion 1: Una formulacion en aerosol, caracterizada porque comprende como mínimo un principio activo seleccionado del grupo que consiste en 20-cetoesteroides y derivados de quinolinona, un propelente HFA licuado, un cosolvente seleccionado entre alcoholes adecuados para uso farmacéutico, y un agente secuestrante seleccionado del grupo que consiste en ácido sulfurico y fosforico, donde la estabilidad química de los principios activos está mejorada, teniendo en cuenta que cuando el principio activo es la 8-hidroxi-5-[(1R)-1-hidroxi-2-[[(1R)-2-(4-metoxifenil)-1-metilo etil]amino]etil]-2 (1H)-quinolinona o su sal clorhidrato (TA 2005), el agente secuestrante no es ácido fosforico. Reivindicacion 17: El uso de un agente secuestrante seleccionado ácido fosforico y sulfurico en una formulacion de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque es para mejorar la estabilidad química del principio activo. Reivindicacion 18: Un inhalador de cartucho presurizado, caracterizado porque contiene una formulacion de acuerdo con cualquiera de las reivindicaciones precedentes. Reivindicacion 22: Un método para llenar un inhalador en aerosol, caracterizado porque comprende: (a) agregar uno o más principios activos a uno o más cosolventes; (b) llenar dicho inhalador con dicha solucion; (c) agregar una cantidad predeterminada de un agente secuestrante, en particular un ácido inorgánico, preferiblemente seleccionad entre ácido fosforico o ácido sulfurico; (d) agregar a dicha solucion un propelente que comprende un hidrofluoroalcano (HFA); y (e) embutir a presion la válvula y llenar con gas; donde dicho ácido fosforico está presente en una cantidad equivalente a entre 0,0004 y 0,040% p/p, preferiblemente entre 0,0008 y 0,020% p/p, más preferiblemente entre 0,001 y 0,010% p/p de ácido fosforico 15 M, calculado en base al peso total de la solucion final, o donde dicho ácido sulfurico está presente en una cantidad equivalente a entre 0,005 y 0,02% p/p, preferiblemente entre 0,001 y 0,01% p/p, más preferiblemente entre 0,001 y 0,0072% p/p, más preferiblemente aun entre 0,002 y 0,0054% p/p de ácido sulfurico 0,075 M, calculado en base al peso total de la composicion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05004233 | 2005-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054230A1 true AR054230A1 (es) | 2007-06-13 |
Family
ID=36490097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060100670A AR054230A1 (es) | 2005-02-25 | 2006-02-23 | Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante |
| ARP150101030A AR099963A2 (es) | 2005-02-25 | 2015-04-06 | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101030A AR099963A2 (es) | 2005-02-25 | 2015-04-06 | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8877164B2 (es) |
| EP (1) | EP1850831B1 (es) |
| JP (1) | JP5259193B2 (es) |
| KR (1) | KR101313959B1 (es) |
| CN (1) | CN101119706B (es) |
| AR (2) | AR054230A1 (es) |
| AU (1) | AU2006218177B2 (es) |
| BR (1) | BRPI0607990A2 (es) |
| CA (1) | CA2594127C (es) |
| EA (1) | EA013405B1 (es) |
| GE (1) | GEP20105040B (es) |
| HK (1) | HK1116337A1 (es) |
| IL (1) | IL184449A0 (es) |
| MA (1) | MA29333B1 (es) |
| MX (1) | MX2007010396A (es) |
| NO (1) | NO20074854L (es) |
| NZ (1) | NZ556376A (es) |
| PE (1) | PE20061011A1 (es) |
| SG (1) | SG159550A1 (es) |
| TN (1) | TNSN07289A1 (es) |
| UA (1) | UA92732C2 (es) |
| WO (1) | WO2006089656A2 (es) |
| ZA (1) | ZA200706870B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112902A2 (en) * | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Medicinal aerosol formulation products with improved chemical stability |
| GB201200525D0 (en) * | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| RU2519653C1 (ru) * | 2013-02-27 | 2014-06-20 | Шолекс Девелопмент Гмбх, | Аэрозольный препарат на основе ипратропия бромида для лечения заболеваний органов дыхания |
| US10034866B2 (en) * | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| US11826382B2 (en) | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US11642372B2 (en) | 2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA939195B (en) * | 1992-12-09 | 1995-06-08 | Boehringer Ingelheim Pharma | Stabilized medicinal aerosol solution formulations |
| SK280911B6 (sk) * | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostriedok |
| DE69424181T2 (de) | 1993-12-20 | 2000-10-19 | Minnesota Mining & Mfg | Flunisolide aerosolformulierungen |
| CA2223385A1 (en) * | 1995-06-07 | 1996-12-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Stabilized steroid compositions |
| IL122752A (en) * | 1995-06-27 | 2001-07-24 | Boehringer Ingelheim Kg | Stable preparations for creating propellant-free sprays |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| IT1313553B1 (it) * | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| AU2001257621A1 (en) * | 2000-05-17 | 2001-11-26 | Chrysalis Technologies, Incorporated | Stabilized budesonide solution and method for making same |
| ME00220B (me) * | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
| ATE465712T1 (de) * | 2002-03-01 | 2010-05-15 | Chiesi Farma Spa | Ultrafeine zusammensetzungen von formoterol |
| DK1497289T3 (da) | 2002-04-12 | 2005-10-24 | Boehringer Ingelheim Pharma | Lægemiddel indeholdende betamimetika og et nyt anticholinergikum |
| US7417051B2 (en) * | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
| DE10230769A1 (de) | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US20040235811A1 (en) * | 2002-10-08 | 2004-11-25 | Sepracor Inc. | Fatty acid modified forms of glucocorticoids |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2006
- 2006-02-13 NZ NZ556376A patent/NZ556376A/en not_active IP Right Cessation
- 2006-02-13 GE GEAP200610279A patent/GEP20105040B/en unknown
- 2006-02-13 WO PCT/EP2006/001287 patent/WO2006089656A2/en active Application Filing
- 2006-02-13 KR KR1020077016131A patent/KR101313959B1/ko not_active IP Right Cessation
- 2006-02-13 CN CN2006800047251A patent/CN101119706B/zh not_active Expired - Fee Related
- 2006-02-13 SG SG201000998-3A patent/SG159550A1/en unknown
- 2006-02-13 CA CA2594127A patent/CA2594127C/en not_active Expired - Fee Related
- 2006-02-13 UA UAA200707949A patent/UA92732C2/ru unknown
- 2006-02-13 MX MX2007010396A patent/MX2007010396A/es active IP Right Grant
- 2006-02-13 EA EA200701805A patent/EA013405B1/ru not_active IP Right Cessation
- 2006-02-13 JP JP2007556521A patent/JP5259193B2/ja not_active Expired - Fee Related
- 2006-02-13 EP EP06706899.9A patent/EP1850831B1/en active Active
- 2006-02-13 AU AU2006218177A patent/AU2006218177B2/en not_active Ceased
- 2006-02-13 BR BRPI0607990-3A patent/BRPI0607990A2/pt not_active IP Right Cessation
- 2006-02-17 PE PE2006000199A patent/PE20061011A1/es not_active Application Discontinuation
- 2006-02-23 AR AR20060100670A patent/AR054230A1/es not_active Application Discontinuation
- 2006-02-24 US US11/361,562 patent/US8877164B2/en not_active Expired - Fee Related
-
2007
- 2007-07-05 IL IL184449A patent/IL184449A0/en unknown
- 2007-07-24 TN TNP2007000289A patent/TNSN07289A1/en unknown
- 2007-08-16 ZA ZA200706870A patent/ZA200706870B/xx unknown
- 2007-09-11 MA MA30220A patent/MA29333B1/fr unknown
- 2007-09-24 NO NO20074854A patent/NO20074854L/no not_active Application Discontinuation
-
2008
- 2008-06-12 HK HK08106480.6A patent/HK1116337A1/xx not_active IP Right Cessation
-
2015
- 2015-04-06 AR ARP150101030A patent/AR099963A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07289A1 (en) | 2008-12-31 |
| SG159550A1 (en) | 2010-03-30 |
| CA2594127A1 (en) | 2006-08-31 |
| GEP20105040B (en) | 2010-07-12 |
| CA2594127C (en) | 2013-10-15 |
| WO2006089656A2 (en) | 2006-08-31 |
| CN101119706A (zh) | 2008-02-06 |
| PE20061011A1 (es) | 2006-12-08 |
| EA013405B1 (ru) | 2010-04-30 |
| JP5259193B2 (ja) | 2013-08-07 |
| JP2008537729A (ja) | 2008-09-25 |
| NO20074854L (no) | 2007-09-24 |
| MX2007010396A (es) | 2007-10-19 |
| EP1850831A2 (en) | 2007-11-07 |
| IL184449A0 (en) | 2007-10-31 |
| WO2006089656A3 (en) | 2006-12-21 |
| ZA200706870B (en) | 2008-11-26 |
| MA29333B1 (fr) | 2008-03-03 |
| EA200701805A1 (ru) | 2008-02-28 |
| NZ556376A (en) | 2010-01-29 |
| CN101119706B (zh) | 2013-04-17 |
| AR099963A2 (es) | 2016-08-31 |
| US20060193785A1 (en) | 2006-08-31 |
| EP1850831B1 (en) | 2015-12-02 |
| KR20070107002A (ko) | 2007-11-06 |
| HK1116337A1 (en) | 2008-12-19 |
| BRPI0607990A2 (pt) | 2009-10-27 |
| KR101313959B1 (ko) | 2013-10-02 |
| AU2006218177A1 (en) | 2006-08-31 |
| AU2006218177B2 (en) | 2012-04-12 |
| US8877164B2 (en) | 2014-11-04 |
| UA92732C2 (ru) | 2010-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088653A (es) | Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva | |
| ES2918299T3 (es) | Composiciones de espuma a base de aerosol emoliente con alto contenido de aceite | |
| AR054230A1 (es) | Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante | |
| SG150558A1 (en) | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | |
| BRPI0510840A (pt) | composição farmacêutica, composição pressurizada, bomba aerossol e uso de uma mistura de análogo de vitamina d e de um corticosteróide | |
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
| WO2007095043A3 (en) | Pharmaceutical formulations | |
| AR029523A1 (es) | Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis | |
| CO5611092A2 (es) | Formulacion superfina de formoterol | |
| DE60308997D1 (de) | Formulierungen zur inhalation | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| AR040450A1 (es) | Formulacion superfina de salmeterol | |
| ATE388099T1 (de) | Inhalator mit mitteln zur verbesserung der chemischen stabilität einer darin enthaltenen medizinischen aerosollösung | |
| ECSP088732A (es) | Aerosoles dosificadores para la administración de preparaciones farmacéuticas | |
| AR039286A1 (es) | Formulacion de aerosol para inhalacion que contiene una sal de tiotropio | |
| AR085059A1 (es) | Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla | |
| NO20064359L (no) | Stabil farmasoytisk losningsformulering fror trykksatt doseringsinhalator | |
| UA88894C2 (ru) | Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением | |
| AR048418A1 (es) | Formulaciones de soluciones medicinales estables para inhaladores de cartucho presurizados | |
| TH86643A (th) | สูตรผสมสารละลาย hfc ที่มีแซลบูทามอล ไฮโดรคลอไรด์ หรือ แซลบูทามอล ซิเทรท | |
| JO2709B1 (ar) | تركيبات لمحاليل طبية ثابتة للاستخدام في أجهزة استنشاق تعطي جرعات مقاسة مضغوطة | |
| CO5300395A1 (es) | Formulaciones farmaceuticas de formoterol o ta2005 en solucion estable para inhaladores presurizados con medicion de dosis | |
| TH97646A (th) | องค์ประกอบทางเภสัชกรรมชนิดเป็นละอองที่มีสองสารแสดงฤทธิ์ หรือมากกว่าและที่อย่างน้อยที่สุดมีหนึ่งสารลดแรงตึงผิว |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |